Thomas Stankovich - 17 Nov 2022 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Issuer symbol
RSLS
Transactions as of
17 Nov 2022
Net transactions value
-$62,938
Form type
4
Filing time
20 Dec 2022, 15:35:43 UTC
Previous filing
10 Nov 2022
Next filing
07 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Award $0 +364,756 +110% $0.000000 697,517 17 Nov 2022 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale $61,826 -364,756 -52% $0.1695 332,761 28 Nov 2022 Direct F2
transaction RSLS Common Stock, $0.001 par value per share Sale $778 -5,144 -1.5% $0.1513 327,617 01 Dec 2022 Direct F3
transaction RSLS Common Stock, $0.001 par value per share Sale $334 -2,213 -0.68% $0.1509 325,404 01 Dec 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued pursuant to a stock bonus granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
F2 These shares were sold to cover taxes and fees in connection with the stock bonus.
F3 On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.